Anyone looking for proof that we need governmental reform will find plenty in an op-ed published June 17th by the CT Mirror, entitled “Georgie Porgie and the Connecticut Budget Cuts.”
Erin Duffy joined Melinta Therapeutics Inc. shortly after its founding, evolving into her current role as chief scientific officer as the company itself evolved from aspiring startup to the cusp of its first antibiotic approval and a pipeline that includes a new class of antibiotics targeting bacterial superbugs.
The kids are out of college. In his rearview mirror is a solid, 32 ½-year career as a certified public accountant who for nearly half that period led one of New England's largest — if not the biggest — independent accounting firm/business consultancies.
Since editorial coverage and advertisements appear next to each other in print, online and on the airwaves, public relations is often thought of as akin to advertising. But PR is more similar to branding. Your brand is the story you tell about yourself. PR is the story told about you.
Think of the construction project to replace the I-84 viaduct through downtown Hartford this way: You can peel the Band-Aid off slowly, or rip it off as quickly as possible.
Q&A talks about the construction industry's focus on energy efficiency and other trends with David Bobrowski, the new director of business development for Erland Construction.
Hartford Business Journal's year-long series on Connecticut bioscience industry returns this week with a look at one of the state's most promising companies, New Haven-based Melinta Therapeutics. Over the next six weeks, HBJ will profile a range of bioscience companies, execs and researchers.
The planned remake of the I-84 viaduct poses many risks and rewards for the city of Hartford as well as the region as whole, and while all stakeholders should have a say in the process, the business community must be top of mind to urban and transportation planners as well as government officials.